Relation Between Previous Lipid-Lowering Therapy and Infarct Size (Creatine Kinase-MB Level) in Patients Presenting With Acute Myocardial Infarction

American Journal of Cardiology

Volumn 102, Issue 9, 2008, Pages 1119-1124

  Aronow, Herbert D ^a   Lincoff, A Michael ^b   Quinn, Martin J ^c   McRae, A Thomas ^d   Gurm, Hitinder S ^e   Houghtaling, Penny L ^b   Granger, Christopher B ^f   Harrington, Robert A ^f   Van de Werf, Franz ^g   Topol, Eric J ^h   Lauer, Michael S ⁱ  

^a ST JOSEPH MERCY HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^d Centennial Heart Cardiovascular Consultants   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h SCRIPPS CLINIC   (United States)

ⁱ NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CREATINE KINASE MB; EPTIFIBATIDE; HEPARIN; RECOMBINANT HIRUDIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; HEART INFARCTION SIZE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

ACUTE CORONARY SYNDROME; AGED; ANTILIPEMIC AGENTS; CHOLESTEROL; CREATINE KINASE, MB FORM; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; NECROSIS; RISK FACTORS;

EID: 54549113334     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.06.032     Document Type: Article

References (29)

1. The GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med 335 (1996) 775-782
2. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 339 (1998) 436-443
3. Hackel D.B., Reimer K.A., Ideker R.E., Mikat E.M., Hartwell T.D., Parker C.B., Braunwald E.B., Buja M., Gold H.K., Jaffe A.S., et al. Comparison of enzymatic and anatomic estimates of myocardial infarct size in man. Circulation 70 (1984) 824-835
4. Licka M., Zimmermann R., Zehelein J., Dengler T.J., Katus H.A., and Kubler W. Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct size. Heart 87 (2002) 520-524
5. Roberts R., Ambos H.D., and Sobel B.E. Estimation of infarct size with MB rather than total CK. Int J Cardiol 2 (1983) 479-492
6. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127 (1997) 757-763
7. Joffe M.M., and Rosenbaum P.R. Invited commentary: propensity scores. Am J Epidemiol 150 (1999) 327-333
8. Austin P.C., and Mamdani M.M. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med 25 (2006) 2084-2106
9. Jones S.P., Gibson M.F., Rimmer III D.M., Gibson T.M., Sharp B.R., and Lefer D.J. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 40 (2002) 1172-1178
10. Wolfrum S., Dendorfer A., Schutt M., Weidtmann B., Heep A., Tempel K., Klein H.H., Dominiak P., and Richardt G. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 44 (2004) 348-355
11. Bybee K.A., Kopecky S.L., Williams B.A., Murphy J.G., and Scott Wright R. Reduced creatine kinase release with statin use at the time of myocardial infarction. Int J Cardiol 96 (2004) 461-466
12. Hoffmann R., Haager P., Suliman H., Christott P., Radke P., Blindt R., and Kelm M. Effect of statin therapy before Q-wave myocardial infarction on myocardial perfusion. Am J Cardiol 101 (2008) 139-143
13. Spencer F.A., Fonarow G.C., Frederick P.D., Wright R.S., Every N., Goldberg R.J., Gore J.M., Dong W., Becker R.C., and French W. Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: National Registry of Myocardial Infarction. Arch Intern Med 164 (2004) 2162-2168
14. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., and Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
15. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
16. Aronow H.D., Topol E.J., Roe M.T., Houghtaling P.L., Wolski K.E., Lincoff A.M., Harrington R.A., Califf R.M., Ohman E.M., Kleiman N.S., et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 357 (2001) 1063-1068
17. Laufs U., Endres M., Custodis F., Gertz K., Nickenig G., Liao J.K., and Bohm M. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 102 (2000) 3104-3110
18. Seljeflot I., Tonstad S., Hjermann I., and Arnesen H. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res 105 (2002) 285-290
19. Hoshida S., Nishida M., Yamashita N., Igarashi J., Hori M., Kamada T., Kuzuya T., and Tada M. Amelioration of severity of myocardial injury by a nitric oxide donor in rabbits fed a cholesterol-rich diet. J Am Coll Cardiol 27 (1996) 902-909
20. Hoshida S., Yamashita N., Otsu K., Kuzuya T., and Hori M. Cholesterol feeding exacerbates myocardial injury in Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol 278 (2000) H256-H262
21. Bulhak A.A., Gourine A.V., Gonon A.T., Sjoquist P.O., Valen G., and Pernow J. Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level. Acta Physiol Scand 183 (2005) 151-159
22. Blanco M., Nombela F., Castellanos M., Rodriguez-Yanez M., Garcia-Gil M., Leira R., Lizasoain I., Serena J., Vivancos J., Moro M.A., Davalos A., and Castillo J. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 69 (2007) 904-910
23. Spencer F.A., Goldberg R.J., Gore J.M., Fox K.A., Avezum A., Agnelli G., Kritharides L., Anderson F.A., Goodman S.G., FitzGerald G., Allegrone J., and Brieger D. Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein > or = 100 mg/dl versus <100 mg/dl. Am J Cardiol 100 (2007) 913-918
24. Kiortsis D.N., Giral P., Bruckert E., and Turpin G. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther 25 (2000) 445-451
25. Simons L.A., Levis G., and Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 164 (1996) 208-211
26. de Lemos J.A., Blazing M.A., Wiviott S.D., Lewis E.F., Fox K.A., White H.D., Rouleau J.L., Pedersen T.R., Gardner L.H., Mukherjee R., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 (2004) 1307-1316
27. Siegel D., Lopez J., and Meier J. Use of cholesterol-lowering medications in the United States from 1991 to 1997. Am J Med 108 (2000) 496-499
28. EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 18 (1997) 1569-1582
29. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., and Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410-418